Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/V_R6F3amR4A/3QMb
Thursday, February 3, 2011
Antares Pharma Announces First Rheumatoid Arthritis Patient Dosed In VIBEX? MTX Clinical Trial
Antares Pharma, Inc. (NYSE Amex: AIS) announced that the first patient has been dosed in a clinical study evaluating the VIBEX? MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional. VIBEX MTX is Antares' proprietary, wholly owned methotrexate injection system designed for rapid self-administration in three simple steps by patients...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment